CancerDrs

Leukemia clinical trials in South Carolina

17 actively recruiting leukemia trials at 15 sites across South Carolina.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full leukemia transparency page →

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Ralph H Johnson VA Medical Center — Charleston, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …

Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in South Carolina:
  • Prisma Health Cancer Institute — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
  • Prisma Health Cancer Institute - Faris — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
  • Prisma Health Cancer Institute - Faris — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in South Carolina:
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
  • Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
  • Prisma Health Cancer Institute - Faris — Greenville, South Carolina
  • Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in South Carolina:
  • Prisma Health Richland Hospital — Columbia, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in South Carolina:
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in South Carolina:
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (…

Sponsor: Medical University of South Carolina
NCT ID: NCT05702853
Sites in South Carolina:
  • Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose c…

Sponsor: Kura Oncology, Inc.
NCT ID: NCT06001788
Sites in South Carolina:
  • Prisma Health — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT02074839
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • McLeod Regional Medical Center — Florence, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina
View on ClinicalTrials.gov →
Recruiting Network

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Recruiting Network

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hyd…

Sponsor: Children's Oncology Group
NCT ID: NCT01790152
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27